Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Plus Decitabine in Post-MPN AML
NCT02257138Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2015
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2015; status: completed.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02257138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257138.